Dionysis Nikolopoulos

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Article: JOURNAL OF TRANSLATIONAL AUTOIMMUNITY. 2025;11:100296
Dysregulation of innate and adaptive lymphoid immunity may have implications for symptom attribution and predict responses to targeted therapies in neuropsychiatric systemic lupus erythematosus
Lindblom J; Barturen G; Beretta L; Toro-Dominguez D; Carnero-Montoro E; Borghi MO; Castillo J; Iacobaeus E; Enman Y; Mohan C; Alarcon-Riquelme ME; Nikolopoulos D; Parodis I
Journal article: RMD OPEN. 2025;11(3):e006009
Systemic lupus erythematosus damage risk index (SLE-DRI): a simple machine learning-based tool for identifying patients at risk for early organ damage
Garantziotis P; Nikolopoulos D; Katechis S; Temiz A; Nothling D-M; Adamichou C; Bergmann C; Sidiropoulos P; Schett G; Fanouriakis A; Boumpas DT; Bertsias G
Article: RHEUMATOLOGY. 2025;64(8):4650-4658
Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab
Depascale R; Da Mutten R; Lindblom J; Cetrez N; Palazzo L; Iaccarino L; Doria A; Nikolopoulos D; Gatto M; Parodis I
Article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84(8):1342-1353
Enhanced B cell and complement cascade gene signatures in patients with neuropsychiatric systemic lupus erythematosus
Nikolopoulos D; Sentis G; Kitsios I; Garantziotis P; Kapsala N; Pieta A; Flouda S; Manolakou T; Nikoloudaki M; Banos A; Chavatza K; Parodis I; Filia A; Bertsias G; Fanouriakis A; Boumpas DT
Article: ANNALS OF THE RHEUMATIC DISEASES. 2025;:S0003-4967(25)04187-1
Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus.
Garantziotis P; Beretta L; Lindblom J; Moysidou G-S; Nikolopoulos D; Grieshaber-Bouyer R; Hagen M; Bergmann C; Wirsching A; Bozec A; PRECISESADS Clinical Consortium; Schneider M; Barturen G; Bertsias G; Boumpas DT; Alarcón-Riquelme ME; Mackensen A; Schett G; Parodis I
Article: RHEUMATOLOGY. 2025;64(7):4257-4266
Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large post hoc analysis of five phase III clinical trials
Grosso G; Giannopoulou N; Tsoi A; Cetrez N; Nikolopoulos D; Lindblom J; Parodis I
Article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84(7):1164-1179
Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1
Lindblom J; Lagutkin D; Sherina N; Idborg H; Beretta L; Borghi MO; Peyper JM; Barturen G; Jakobsson P-J; Alarcon-Riquelme ME; Nikolopoulos D; Parodis I
Article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84(7):1180-1194
New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
Parodis I; Lagutkin D; Lindblom J; Idborg H; Beretta L; Borghi MO; Peyper JM; Barturen G; Jakobsson P-J; Alarcon-Riquelme ME; Sherina N; Nikolopoulos D
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2025;83:264-265
INTERFERON AND B LYMPHOCYTE DYSREGULATION PATTERNS DETERMINE DISTINCT LUPUS NEPHRITIS SUBGROUPS WITH DIFFERENTIAL ANTICIPATED RESPONSE TO TARGETED THERAPIES
Parodis I; Lindblom J; Toro-Dominguez D; Beretta L; Borghi MO; Castillo J; Carnero-Montoro E; Enman Y; Mohan C; Alarcon-Riquelme M; Barturen G; Nikolopoulos D
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84:2177
ABS0123 DISTINCT MOLECULAR RESPONSES TO CD19 CAR-T CELL THERAPY VERSUS STANDARD PHARMACOTHERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS
Garantziotis P; Beretta L; Lindblom J; Nikolopoulos D; Grieshaber-Bouyer R; Moysidou GS; Hagen M; Wirsching A; Taubmann J; Bergmann C; Bozec A; Barturen G; Fanouriakis A; Bertsias GK; Schneider M; Boumpas D; Alarcon-Riquelme M; Schett G; Parodis I
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84:1267-1268
POS1203 GLYCOSYLATION CHANGES OF IgG, C3 AND ALPHA-1-ACID GLYCOPROTEIN (AGP) OVER ONE YEAR OF TREATMENT FOR INCIDENT LUPUS NEPHRITIS ARE ASSOCIATED WITH RENAL OUTCOME
Nikolopoulos D; Pučić-Baković M; Šimunović J; Patenaude AM; Vučković F; Pribić T; Tamirou F; Lauc G; Houssiau F; Parodis I
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84:2210
ABS0508 MACHINE LEARNING APPROACHES FOR PREDICTING EARLY ORGAN DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS
Temiz A; Nikolopoulos D; Garantziotis P; Schett G; Fanouriakis A; Boumpas D; Bertsias GK
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2025;83:260
MECHANISTIC BASIS FOR THE DISEASE MODIFYING EFFECTS OF BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND MOLECULAR PREDICTORS OF RESPONSE BY BLOOD TRANSCRIPTOME ANALYSIS: EVIDENCE FOR A ROLE OF THE INNATE IMMUNITY (NEUTROPHILS, COMPLEMENT AND INTERFERON-Α) AND THE DNA DAMAGE RESPONSE
Moysidou GS; Garantziotis P; Grigoriou M; Nikolopoulos D; Sentis G; Nikoleri D; Filia A; Nikoloudaki M; Stergioti E; Malissovas N; Kapsala N; Fanouriakis A; Bertsias GK; Boumpas D
Article: RHEUMATOLOGY. 2025;64(6):3797-3805
Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting
Gomez A; Walhelm T; Loeff FC; Jonsen A; Nikolopoulos D; van den Broek B; Bengtsson AA; de Vries A; Rispens T; Sjowall C; Parodis I
Journal article: JOURNAL OF RHEUMATOLOGY. 2025;52(Suppl 1):45
NOVEL IgG AND IgA AUTOANTIBODIES IN TWO INDEPENDENT COHORTS ASSOCIATE WITH GLOBAL AND ORGAN-SPECIFIC DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS: IMPLICATIONS FOR ANTI-LIN28A AND ANTI-IRF5
Lindblom J; Lagutkin D; Sherina N; Idborg H; Beretta L; Borghi MO; Consortium PC; Peyper JM; Barturen G; Jakobsson P-J; Alarcón-Riquelme M; Nikolopoulos D; Parodis I
Journal article: JOURNAL OF RHEUMATOLOGY. 2025;52(Suppl 1):8
DISTINCT MOLECULAR PROFILES OF REMISSION POST-CD19 CAR-T CELL THERAPY VERSUS STANDARD IMMUNOSUPPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS
Garantziotis P; Beretta L; Lindblom J; Nikolopoulos D; Bertsias G; Hagen M; Taubmann J; Wirsching A; Bozec A; Grieshaber-Bouyer R; Consortium PC; Schneider M; Barturen G; Boumpas D; Alarcón-Riquelme M; Schett G; Parodis I
Journal article: JOURNAL OF RHEUMATOLOGY. 2025;52(Suppl 1):249
DRUG LEVELS AND ANTI-DRUG ANTIBODIES OVER 2 YEARS OF BELIMUMAB THERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS
Gomez A; Walhelm T; Loeff F; Jönsen A; Nikolopoulos D; Van Den Broek B; Bengtsson A; De Vries A; Rispens T; Sjöwall C; Parodis I
Journal article: JOURNAL OF RHEUMATOLOGY. 2025;52(Suppl 1):219-220
NEW IGG AND IGA AUTOANTIBODY SPECIFICITIES TARGETING DNA- AND RNA-BINDING PROTEINS DIFFERENTIATE SYSTEMIC LUPUS ERYTHEMATOSUS FROM HEALTHY INDIVIDUALS AND OTHER AUTOIMMUNE DISEASES
Parodis I; Lagutkin D; Lindblom J; Idborg H; Beretta L; Borghi MO; Consortium PC; Peyper JM; Barturen G; Jakobsson P-J; Alarcón-Riquelme M; Sherina N; Nikolopoulos D
Article: RHEUMATOLOGY. 2025;64(5):2715-2722
Can we predict kidney involvement in patients with systemic lupus erythematosus? A retrospective cohort study with independent validation
Katechis S; Nikolopoulos D; Flouda S; Adamichou C; Chavatza K; Kapsala N; Katsimbri P; Bertsias G; Boumpas DT; Fanouriakis A
Article: RHEUMATOLOGY. 2025;64(5):2697-2705
Trajectories of disease evolution upon treatment initiation in systemic lupus erythematosus: results from four clinical trials of belimumab
Parodis I; Lindblom J; Tsoi A; Palazzo L; Sporre KB; Enman Y; Nikolopoulos D; Beretta L
Article: RHEUMATOLOGY ADVANCES IN PRACTICE. 2025;9(2):rkaf032
Predicting EQ-5D full health state in systemic lupus erythematosus using machine learning algorithms
Botto J; Cetrez N; Nikolopoulos D; Regardt M; Heintz E; Lindblom J; Parodis I
Article: RMD OPEN. 2025;11(1):e005050
Transcriptome analysis to decipher the molecular underpinnings of response to treatment in systemic lupus erythematosus
Garantziotis P; Moysidou GS; Kapsala N; Flouda S; Nikolopoulos D; Chavatza K; Sentis G; Filia A; Malissovas N; Pieta A; Banos A; Katechis S; Fanouriakis A; Bertsias G; Boumpas DT
Article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84(2):262-273
Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways
Moysidou G-S; Garantziotis P; Sentis G; Nikoleri D; Malissovas N; Nikoloudaki M; Stergioti E-M; Polia S; Paschalidis N; Filia A; Grigoriou M; Nikolopoulos D; Kapsala N; Katechis S; Fanouriakis A; Bertsias G; Boumpas DT
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2024;:ard-2024-226051
Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways.
Moysidou G-S; Garantziotis P; Sentis G; Nikoleri D; Malissovas N; Nikoloudaki M; Stergioti E-M; Polia S; Paschalidis N; Filia A; Grigoriou M; Nikolopoulos D; Kapsala N; Katechis S; Fanouriakis A; Bertsias G; Boumpas DT
Article: JOURNAL OF IMMUNOLOGICAL METHODS. 2024;532:113717
Belimumab concentration measurements using a homologous anti-idiotype immunoassay
Loeff FC; Parodis I; Walhelm T; Jonsen A; Nikolopoulos D; Sjowall C; Bengtsson AA; Kos D; van Leeuwen A; van den Broek B; Dijk L; Jeremiasse J; Blomjous BS; Voskuyl AE; Wolbink GJ; Bultin IEM; Rispens T
Article: RHEUMATOLOGY. 2024;63(9):2494-2502
Patients with NPSLE experience poorer HRQoL and more fatigue than SLE patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity
Nikolopoulos D; Cetrez N; Lindblom J; Palazzo L; Enman Y; Parodis I
Article: RHEUMATOLOGY INTERNATIONAL. 2024;44(9):1679-1689
Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials
Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Article: ANNALS OF THE RHEUMATIC DISEASES. 2024;83(9):1132-1143
Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events
Nikolopoulos D; Loukogiannaki C; Sentis G; Garantziotis P; Manolakou T; Kapsala N; Nikoloudaki M; Pieta A; Flouda S; Parodis I; Bertsias G; Fanouriakis A; Filia A; Boumpas DT
Article: KIDNEY INTERNATIONAL REPORTS. 2024;9(6):1817-1835
Interferon and B-cell Signatures Inform Precision Medicine in Lupus Nephritis
Parodis I; Lindblom J; Toro-Dominguez D; Beretta L; Borghi MO; Castillo J; Carnero-Montoro E; Enman Y; Mohan C; Alarcon-Riquelme ME; Barturen G; Nikolopoulos D; PRECISESADS Clinical Consortium OBOPREC
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2024;83:207-208
LYMPHOCYTE, NK CELL AND MITOCHONDRIAL GENE DYSREGULATION PATTERNS SEPARATE PATIENTS WITH NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS INTO DISTINCT SUBGROUPS WITH DIFFERENTIAL ANTICIPATED RESPONSE TO TARGETED THERAPIES
Lindblom J; Nikolopoulos D; Toro-Dominguez D; Carnero-Montoro E; Borghi MO; Castillo J; Enman Y; Mohan C; Beretta L; Alarcon-Riquelme M; Barturen G; Parodis I; Iacobaeus E
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2024;83:400-401
MACHINE LEARNING-BASED APPROACHES TOWARDS STRATIFICATION OF DISEASE SEVERITY AND ORGAN DAMAGE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Garantziotis P; Nikolopoulos D; Adamichou C; Fanouriakis A; Repa A; Boumpas D; Sidiropoulos P; Bertsias GK
Article: LUPUS. 2024;33(2):166-171
Impaired serotonin synthesis in hippocampus of murine lupus represents an early neuropsychiatric event
Nikolopoulos D; Nakos-Bimpos M; Manolakou T; Polissidis A; Boumpas DT
Article: BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY. 2023;37(4):101894
Reframing health disparities in SLE: A critical reassessment of racial and ethnic differences in lupus disease outcomes
Parodis I; Lanata C; Nikolopoulos D; Blazer A; Yazdany J
Article: FRONTIERS IN IMMUNOLOGY. 2023;14:1203848
A network-based approach reveals long non-coding RNAs associated with disease activity in lupus nephritis: key pathways for flare and potential biomarkers to be used as liquid biopsies
Sentis G; Loukogiannaki C; Malissovas N; Nikolopoulos D; Manolakou T; Flouda S; Grigoriou M; Banos A; Boumpas DTT; Filia A
Article: ANNALS OF THE RHEUMATIC DISEASES. 2023;82(5):646-657
Microglia activation in the presence of intact blood-brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus
Nikolopoulos D; Manolakou T; Polissidis A; Filia A; Bertsias G; Koutmani Y; Boumpas DT
Journal article: BMC GENOMICS. 2023;24(1):207
Restoration of aberrant gene expression of monocytes in systemic lupus erythematosus via a combined transcriptome-reversal and network-based drug repurposing strategy
Nikolakis D; Garantziotis P; Sentis G; Fanouriakis A; Bertsias G; Frangou E; Nikolopoulos D; Banos A; Boumpas DT
Journal article: LUPUS. 2023;32(2):225-230
Relapses are common in severe hematologic systemic lupus erythematosus and may be prevented by early institution of immunosuppressive agents: Α real-life single-center study
Moysidou G-S; Garantziotis P; Nikolopoulos D; Katsimbri P; Fanouriakis A; Boumpas DT
Journal article: FRONTIERS IN IMMUNOLOGY. 2023;13:1074044
Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study
Nikoloudaki M; Nikolopoulos D; Koutsoviti S; Flouri I; Kapsala N; Repa A; Katsimbri P; Theotikos E; Pitsigavdaki S; Pateromichelaki K; Bertsias A; Elezoglou A; Sidiropoulos P; Fanouriakis A; Boumpas D; Bertsias G
Journal article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2023;41(1):74-81
From first symptoms to diagnosis of systemic lupus erythematosus: mapping the journey of patients in an observational study
Kapsala NN; Nikolopoulos DS; Flouda SP; Chavatza AP; Tseronis DD; Aggelakos MD; Katsimbri PP; Bertsias GK; Fanouriakis AC; Boumpas DT
Article: SCIENCE ADVANCES. 2022;8(43):eabo5840
ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus
Manolakou T; Nikolopoulos D; Gkikas D; Filia A; Samiotaki M; Stamatakis G; Fanouriakis A; Politis P; Banos A; Alissafi T; Verginis P; Boumpas DT
Article: ANNALS OF THE RHEUMATIC DISEASES. 2022;81(10):1409-1419
Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis
Frangou E; Garantziotis P; Grigoriou M; Banos A; Nikolopoulos D; Pieta A; Doumas SA; Fanouriakis A; Hatzioannou A; Manolakou T; Alissafi T; Verginis P; Athanasiadis E; Dermitzakis E; Bertsias G; Filia A; Boumpas DT
Journal article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2022;40(9):1769-1778
Remission or low disease activity at pregnancy onset are linked to improved foetal outcomes in women with systemic lupus erythematosus: results from a prospective observational study
Ntali S; Nikolopoulos D; Pantazi L; Emmanouilidou E; Papagoras C; Fanouriakis A; Dimopoulou D; Kallitsakis I; Boki K; Dania V; Sidiropoulos PI; Boumpas DT; Bertsias G
Journal article: RHEUMATOLOGY INTERNATIONAL. 2022;42(8):1307-1319
Tailored treatment strategies and future directions in systemic lupus erythematosus
Nikolopoulos D; Fotis L; Gioti O; Fanouriakis A
Journal article: FRONTIERS IN NEUROLOGY. 2022;13:889613
Demyelinating Syndromes in Systemic Lupus Erythematosus: Data From the "Attikon" Lupus Cohort
Nikolopoulos D; Kitsos D; Papathanasiou M; Kapsala N; Garantziotis P; Pieta A; Gioti O; Grivas A; Voumvourakis K; Boumpas D; Fanouriakis A
Journal article: AMERICAN JOURNAL OF MEDICINE. 2022;135(2):244-253.e3
First Diagnosis of Systemic Lupus Erythematosus in Hospitalized Patients: Clinical Phenotypes and Pitfalls for the Non-Specialist
Kapsala N; Nikolopoulos D; Flouda S; Chavatza A; Tseronis D; Aggelakos M; Katsimbri P; Bertsias G; Fanouriakis A; Boumpas DT
Journal article: RHEUMATOLOGY. 2021;60(9):4166-4174
Demyelination with autoimmune features: a distinct clinical entity? Results from a longitudinal cohort
Nikolopoulos D; Kitsos D; Papathanasiou M; Chondrogianni M; Theodorou A; Garantziotis P; Pieta A; Doskas T; Bertsias G; Voumvourakis K; Boumpas DT; Fanouriakis A
Article: ANNALS OF THE RHEUMATIC DISEASES. 2021;80(9):1175-1182
Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients
Chavatza K; Kostopoulou M; Nikolopoulos D; Gioti O; Togia K; Andreoli L; Aringer M; Boletis J; Doria A; Houssiau FA; Jayne D; Mosca M; Svenungsson E; Tincani A; Bertsias G; Fanouriakis A; Boumpas DT
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2021;80(6):758-766
Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus
Adamichou C; Genitsaridi I; Nikolopoulos D; Nikoloudaki M; Repa A; Bortoluzzi A; Fanouriakis A; Sidiropoulos P; Boumpas DT; Bertsias GK
Journal article: EXPERT REVIEW OF CLINICAL IMMUNOLOGY. 2021;17(4):317-329
Treatment of neuropsychiatric systemic lupus erythematosus: clinical challenges and future perspectives
Nikolopoulos D; Fanouriakis A; Bertsias G
Journal article: CLINICAL RHEUMATOLOGY. 2021;40(4):1447-1456
The role of plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis
Bellos I; Michelakis I; Nikolopoulos D
Article: SEMINARS IN ARTHRITIS AND RHEUMATISM. 2020;50(6):1387-1393
Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study
Yavuz S; Cansu DU; Nikolopoulos D; Crisafulli F; Antunes AM; Adamichou C; Reid S; Stagnaro C; Andreoli L; Tincani A; Moraes-Fontes MF; Mosca M; Leonard D; Jonsen A; Bengtsson A; Svenungsson E; Gunnarsson I; Dahlqvist SR; Sjowall C; Bertsias G; Fanouriakis A; Ronnblom L
Journal article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(3):330
Interstitial Pneumonia with Autoimmune Features (IPAF): A Single-Centre, Prospective Study.
Karampeli M; Thomas K; Flouda S; Chavatza A; Nikolopoulos D; Pieta A; Tseronis D; Aggelakos M; Kassara D; Tzavara V; Katsimbri P; Boumpas D; Karageorgas T
Journal article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(3):366
Mitophagy Balance in Various Cell Subsets in Patients with ANCA-Associated Vasculitis and Correlation with the Presence of Anti-Neutrophil Cytoplasmic Antibodies.
Banos A; Thomas K; Garantziotis P; Malissovas N; Filia A; Pieta A; Nikolopoulos D; Moustafa S; Panagiotopoulos A; Boumpas DT; Vassilopoulos D
Journal article: LUPUS SCIENCE & MEDICINE. 2020;7(1):e000394
Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease
Nikolopoulos DS; Kostopoulou M; Pieta A; Flouda S; Chavatza K; Banos A; Boletis J; Katsimbri P; Boumpas DT; Fanouriakis A
Journal article: LUPUS. 2020;29(5):514-522
Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the 'Attikon' cohort
Nikolopoulos D; Kostopoulou M; Pieta A; Karageorgas T; Tseronis D; Chavatza K; Flouda S; Rapsomaniki P; Banos A; Kremasmenou E; Tzavara V; Katsimbri P; Fanouriakis A; Boumpas DT
Article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(1):87-91
Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus.
Adamichou C; Flouri I; Fanouriakis A; Nikoloudaki M; Nikolopoulos D; Repa A; Boki K; Chatzidionysiou K; Garyfallos A; Boumpas D; Sidiropoulos P; Bertsias G
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2020;79(2):232-241
In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment
Adamichou C; Nikolopoulos D; Genitsaridi I; Bortoluzzi A; Fanouriakis A; Papastefanakis E; Kalogiannaki E; Gergianaki I; Sidiropoulos P; Boumpas DT; Bertsias GK
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2020;79(2):242-253
Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus
Grigoriou M; Banos A; Filia A; Pavlidis P; Giannouli S; Karali V; Nikolopoulos D; Pieta A; Bertsias G; Verginis P; Mitroulis I; Boumpas DT
Journal article: CURRENT OPINION IN RHEUMATOLOGY. 2019;31(6):669-677
Update on the pathogenesis of central nervous system lupus
Nikolopoulos D; Fanouriakis A; Boumpas DT
Journal article: BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY. 2019;33(4):101425
Suspected systemic rheumatic diseases in patients presenting with cytopenias
Nikolopoulos D; Adamichou C; Bertsias G
Journal article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2019;30(1):7-15
Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management.
Nikolopoulos D; Fanouriakis A; Boumpas DT
Journal article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2018;29(4):228
Birth Registry of Women With Systematic Lupus Erythematosus: The Greek Experience.
Ntali S; Pantazi L; Mpoki K; Nikolopoulos D; Fanouriakis A; Kallitsakis I; Papagoras C; Dimopoulou D; Kteniadaki E; Emmanouilidou E; Chania V; Bertsias G
Journal article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2018;29(4):232
Comparative analysis of the sensitivity and specificity of the classification criteria and correlation with prognosis of disease in patients with Systemic Lupus Erythematosus.
Adamichou C; Nikolopoulos D; Papastefanakis E; Kalogiannaki E; Gergianaki I; Kountouri A; Repa A; Avgoustidis N; Kougkas N; Sidiropoulos P; Fanouriakis A; Bertsias G
Visa fler

Alla övriga publikationer

Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2025;83:942-943
NOVEL IGG AND IGA AUTOANTIBODIES DIFFERENTIATING SYSTEMIC LUPUS ERYTHEMATOSUS FROM PRIMARY SJÖGREN'S SYNDROME AND SYSTEMIC SCLEROSIS
Parodis I; Nikolopoulos D; Lindblom J; Beretta L; Cetrez N; Peyper J; Barturen G; Jakobsson PJ; Alarcon-Riquelme M; Idborg H
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2025;83:942.1-94942
IGG AND IGA AUTOANTIBODIES AGAINST NOVEL ANTIGEN SPECIFICITIES IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH DIFFERENTIAL UNDERLYING MECHANISMS HERALDING PROMISE FOR EARLY DIAGNOSIS
Parodis I; Nikolopoulos D; Lindblom J; Beretta L; Cetrez N; Peyper J; Barturen G; Jakobsson PJ; Alarcon-Riquelme M; Idborg H
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2025;84
GLYCOSYLATION CHANGES OF IgG, C3 AND ALPHA-1-ACID GLYCOPROTEIN (AGP) OVER ONE YEAR OF TREATMENT FOR INCIDENT LUPUS NEPHRITIS ARE ASSOCIATED WITH RENAL OUTCOME
Nikolopoulos D; Pucic-Bakovic M; Simunovic J; Patenaude AM; Vuckovic F; Pribic T; Tamirou F; Lauc G; Houssiau F; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2025;84:2177
DISTINCT MOLECULAR RESPONSES TO CD19 CAR-T CELL THERAPY VERSUS STANDARD PHARMACOTHERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS
Garantziotis P; Beretta L; Lindblom J; Nikolopoulos D; Grieshaber-Bouyer R; Moysidou GS; Hagen M; Wirsching A; Taubmann J; Bergmann C; Bozec A; Barturen G; Fanouriakis A; Bertsias GK; Schneider M; Boumpas D; Alarcon-Riquelme M; Schett G; Parodis I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2024;76:3773-3774
Selective Targeting of One-Carbon Metabolism to Combat Rheumatoid Arthritis
Manolakou T; Boddul S; Sentis G; Panagias MA; Samiotaki M; Nikolopoulos D; Slipicevic A; Sanjiv K; Henriksson M; Mortusewicz O; Chatzidionysiou A; Jakobsson P-J; Helleday T
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2024;76:4909-4910
Blood Transcriptome Analysis Reveals Enhanced B Cell and Complement Cascade Signatures in Patients with Major Neuropsychiatric Systemic Lupus Erythematosus
Nikolopoulos D; Sentis G; Kitsos J; Garantziotis P; Kapsala N; Pieta A; Nikoloudaki M; Manolakou T; Flouda S; Parodis I; Filia A; Bertsias G; Fanouriakis A; Boumpas D
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2024;76:3439-3440
IgG and IgA anti-LIN28A Outperform Anti-dsDNA and anti-Sm in Distinguishing SLE from Health and Other Autoimmune Diseases
Parodis I; Nikolopoulos D; Lindblom J; Lagutkin D; Beretta L; Borghi MO; Peyper J; Barturen G; Jakobsson P-J; Alarcon-Riquelme M; Sherina N; Idborg H
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2024;76:3050-3053
Trajectories of Disease Evolution upon Treatment Initiation in Systemic Lupus Erythematosus: Pooled Results from Three Randomized Clinical Trials of Belimumab
Parodis I; Lindblom J; Tsoi A; Nikolopoulos D; Beretta L
Review: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2024;35(2):319
The Multiple Faces of Systemic Lupus Erythematosus: Pearls and Pitfalls for Diagnosis
Kapsala N; Nikolopoulos D; Fanouriakis A
Review: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2024;35(2):328
Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus Erythematosus
Nikolopoulos D; Lourenco MH; Depascale R; Triantafyllias K; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2024;83:1006-1007
BELIMUMAB EFFICACY IN MUCOCUTANEOUS SYSTEMIC LUPUS ERYTHEMATOSUS: A LARGE POST-HOC ANALYSIS INTEGRATING DATA FROM FIVE PHASE III RANDOMISED CONTROLLED TRIALS
Grosso G; Giannopoulou N; Tsoi A; Cetrez N; Nikolopoulos D; Lindblom J; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2024;83:23-24
THE MOLECULAR LANDSCAPE OF ANTIPHOSPHOLIPID SYNDROME IN SYSTEMIC LUPUS ERYTHEMATOSUS: DISTINCT TRANSCRIPTIONAL PROFILES IN VENOUS VERSUS ARTERIAL EVENTS, WITH POTENTIAL THERAPEUTIC IMPLICATIONS
Nikolopoulos D; Loukogiannaki C; Sentis G; Garantziotis P; Manolakou T; Kapsala N; Nikoloudaki M; Pieta A; Flouda S; Parodis I; Bertsias GK; Fanouriakis A; Filia A; Boumpas D
Review: EXPERT OPINION ON PHARMACOTHERAPY. 2024;25(6):705-716
Advances in the pharmacological management of systemic lupus erythematosus
Tsoi A; Nikolopoulos D; Parodis I
Conference publication: 2024;:a14-a15
O11 Unsupervised machine-learning identifies distinct clusters based on B cell phenotyping and autoantibody profiles in patients with systemic lupus erythematosus
Gatto M; Depascale R; Cetrez N; Lindblom J; Nikolopoulos D; Doria A; Parodis I
Conference publication: 2024;:a86.1-a8a86
P62 Machine learning approaches for prediction of renal flares in systemic lupus erythematosus: knowledge-driven models outperformed data-driven models
Cetrez N; Lindblom J; Mutten RD; Nikolopoulos D; Parodis I
Conference publication: 2024;:a24-a25
O23 Interferon upregulation and B and plasma cell gene dysregulation patterns reveal three distinct lupus nephritis subgroups with differential anticipated response to targeted therapies
Parodis I; Lindblom J; Toro-Domínguez D; Beretta L; Borghi MO; Castillo J; Carnero-Montoro E; Enman Y; Mohan C; Alarcón-Riquelme ME; Barturen G; Nikolopoulos D
Conference publication: 2024;:a17-a18
O15 B cell, T cell, cytotoxic/NK cell, and mitochondrial gene dysregulation patterns separate neuropsychiatric systemic lupus erythematosus patients into two distinct subgroups with differential anticipated response to targeted therapies
Lindblom J; Nikolopoulos D; Toro-Domínguez D; Carnero-Montoro E; Borghi MO; Castillo J; Iacobaeus E; Enman Y; Mohan C; Beretta L; Alarcón-Riquelme ME; Barturen G; Parodis I
Conference publication: 2024;:a59.1-a5a59
P23 Presence of anti-Sm autoantibodies is associated with abatement of attainability of LLDAS and DORIS remission in systemic lupus erythematosus
Lourenço MH; Cetrez N; Tsoi A; Lindblom J; Nikolopoulos D; Parodis I
Conference publication: 2024;:a28.2-a2a29
O28 Unveiling the impact of neuropsychiatric involvement in systemic lupus erythematosus on damage accrual
Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Conference publication: 2024;:a119.1-a1a119
P110 Impact of neuropsychiatric involvement on health-related quality of life in patients with systemic lupus erythematosus
Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Conference publication: 2024;:a85.2-a8a86
P61 Harnessing machine learning to predict neuropsychiatric events in systemic lupus erythematosus
Cetrez N; Lindblom J; Mutten RD; Nikolopoulos D; Parodis I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2023;75:2880-2881
Impact of Neuropsychiatric Involvement on Health-related Quality of Life in Patients with Systemic Lupus Erythematosus
Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2023;75:2879-2880
Unveiling the Impact of Neuropsychiatric Involvement in Systemic Lupus Erythematosus on Damage Accrual
Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2023;75:4580-4581
Machine Learning Approaches for Prediction of Renal Flares in Systemic Lupus Erythematosus: Knowledge-Driven Models Outperformed Data-Driven Models
Cetrez N; Lindblom J; Da Mutten R; Nikolopoulos D; Parodis I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2023;75:4596-4597
Predicting Remission and Low Disease Activity Attainment in Patients with Systemic Lupus Erythematosus
Da Mutten R; Cetrez N; Lindblom J; Oon S; Nikolopoulos D; Nikpour M; Parodis I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2023;75:1081-1082
Harnessing Machine Learning to Predict Neuropsychiatric Events in Systemic Lupus Erythematosus
Cetrez N; Lindblom J; Da Mutten R; Nikolopoulos D; Parodis I
Review: FRONTIERS IN MEDICINE. 2023;10:1217147
Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
Nikolopoulos D; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:8
EPITRANSCRIPTOME EDITING REPRESENTS AN ADDITIONAL LAYER OF IMMUNE-RELATED EPIGENETIC MEMORY OF MONOCYTES IN HUMAN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Banos A; Kloetgen A; Katsiki K; Filia A; Nikolopoulos D; Tsirigos A; Boumpas D
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:1246-1247
RESTORATION OF ABERRANT GENE EXPRESSION OF MONOCYTES IN SYSTEMIC LUPUS ERYTHEMATOSUS VIA A COMBINED TRANSCRIPTOME-REVERSAL AND NETWORK-BASED DRUG REPURPOSING STRATEGY
Nikolakis D; Garantziotis P; Sentis G; Fanouriakis A; Bertsias G; Frangou E; Nikolopoulos D; Banos A; Boumpas D
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:1515
THE ATTRIBUTION OF NEUROPSYCHIATRIC EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM "ATTIKON" LUPUS COHORT
Nikolopoulos D; Kapsala N; Gioti O; Flouda S; Pieta A; Chavatza K; Karageorgas T; Tseronis D; Katsimbri P; Boumpas D; Fanouriakis A
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:484
DISRUPTED HIPPOCAMPAL NEUROGENESIS MEDIATED BY IL-6 AND IL-18 INDUCE NEUROPSYCHIATRIC CHANGES IN MURINE LUPUS
Nikolopoulos D; Manolakou T; Polissidis A; Filia A; Koutmani Y; Boumpas D
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2022;81:341
A PREDOMINANT NON-SPECIFIC INTERSTITIAL PNEUMONIA PATTERN AND ABERRANT TRANSCRIPTOMIC NEUTROPHIL-MEDIATED IMMUNITY CHARACTERIZE A CONTEMPORARY RA-ILD COHORT
Flouda S; Grivas A; Kapsala N; Grigoriou M; Nikolopoulos D; Filia A; Sentis G; Chavatza K; Aggelakos M; Moysidou GS; Kosmetatou M; Tseronis D; Katsimpri P; Karageorgas T; Fanouriakis A; Boumpas D
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2021;80:635-636
EULAR RECOMMENDATION-BASED QUALITY INDICATORS (QIS) FOR SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): ELABORATION, FINAL SET, PERFORMANCE AND INITIAL VALIDATION
Chavatza K; Kostopoulou M; Nikolopoulos D; Gioti O; Togia K; Flouda S; Kapsala N; Kosmetatou M; Moysidou GS; Grivas A; Pieta A; Ntourou A; Rapsomaniki P; Gerogianni T; Tseronis D; Aggelakos M; Karageorgas T; Katsimpri P; Andreoli L; Aringer M; Boletis N; Doria A; Houssiau F; Jayne D; Mosca M; Svenungsson E; Tincani A; Bertsias G; Fanouriakis A; Boumpas D
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2021;80:439-440
COMBINED ANALYSIS OF METABOLIC AND TRANSCRIPTOMIC KIDNEY PROFILES OF NZW/B-F1 MURINE LUPUS UNCOVERS BIOLOGICAL MECHANISMS PRECEDING THE ONSET OF NEPHRITIS
Manolakou T; Tsiara I; Nikolopoulos D; Garantziotis P; Benaki D; Gikas E; Frangou E; Mikroa E; Boumpas D
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2021;80:21-22
HIPPOCAMPAL IMMUNE CELL TRAFFICKING AND A MYELOID PREDOMINANT INFLAMMATORY RESPONSE WITH ENHANCED ANTIGEN PRESENTATION AND DECREASED LEVELS OF NEUROTRANSMITTERS UNDERLY THE NEUROPSYCHIATRIC PHENOTYPE OF THE NZW/NZB MURINE LUPUS MODEL
Nikolopoulos D; Manolakou T; Filia A; Nakos-Bimpos M; Polissidis A; Boumpas D
Review: CURRENT VASCULAR PHARMACOLOGY. 2020;18(6):549-565
Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention
Kostopoulou M; Nikolopoulos D; Parodis I; Bertsias G
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:868-869
BIRTH REGISTRY OF WOMEN WITH SYSTEMATIC LUPUS ERYTHEMATOSUSAND COURSE OF THE DISEASE DURING FIRST YEARS POST-PARTUM-THE GREEK EXPERIENCE
Ntali S; Pantazi L; Boki K; Nikolopoulos D; Fanouriakis A; Dimopoulou D; Kallitsakis I; Papagoras C; Dania V; Emmanouilidou E; Bertsias G
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:665-666
THERAPEUTIC TARGETS AND QUALITY INDICATORS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), DEFINED ACCORDING TO THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS: DATA FROM THE "ATTIKON" LUPUS COHORT
Havatza K; Togia K; Flouda S; Pieta A; Gioti O; Nikolopoulos D; Kapsala N; Ntourou A; Rapsomaniki P; Gerogianni T; Tseronis D; Aggelakos M; Karageorgas T; Katsimpri P; Bertsias G; Thomas K; Boumpas D; Fanouriakis A
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:1895-1896
INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES (IPAF): A SINGLE CENTER, PROSPECTIVE STUDY
Karampeli M; Thomas K; Tseronis D; Aggelakos M; Kassara D; Havatza K; Flouda S; Nikolopoulos D; Pieta A; Tzavara V; Katsimbri P; Boumpas D; Karageorgas T
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:1688-1689
GENDER DIFFERENCES IN PSORIATIC ARTHRITIS DISEASE CHARACTERISTICS: EVIDENCE FOR WORSE DISEASE IN WOMEN.
Grivas A; Kapniari I; Tzannis K; Tseronis D; Aggelakos M; Kassara D; Havatza K; Flouda S; Nikolopoulos D; Karageorgas T; Papadavid E; Boumpas D; Katsimpri P
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:405
TRENDS OF SEVERITY, PROGRESSION AND BURDEN OF DISEASE IN THE "ATTIKON" SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) COHORT: EVIDENCE FOR THE RULE OF "ONE THIRD" IN DISEASE SEVERITY
Nikolopoulos D; Pieta A; Kostopoulou M; Erden A; Katsimbri P; Boumpas D; Fanouriakis A
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:420-421
WHAT DO HEMATOLOGICAL ABNORMALITIES TELL US IN SLE? RESULTS FROM TWO INDEPENDENT MULTICENTER EUROPEAN SLE COHORTS
Yavuz S; Cansu D; Nikolopoulos D; Crisafulli F; Arantunes AM; Adamichou C; Reid S; Satgnaro C; Andreoli L; Tincani A; Moraes-Fontes M; Bertsias G; Mosca M; Leonard D; Fanouriakis A; Ronnblom L
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:220
RNA SEQUENCING AND MACHINE LEARNING TECHNIQUES PREDICT MAJOR ORGAN INVOLVEMENT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Filia A; Bertsias G; Panousis N; Nikolopoulos D; Dermitzakis E; Boumpas D
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:792
THE EULAR/ACR 2018 AND SLICC 2012 HAVE INCREASED SENSITIVITY AGAINST THE ACR 1997 CLASSIFICATION CRITERIA AND CLASSIFY NON-OVERLAPPING GROUPS OF SLE PATIENTS: SIMULTANEOUS APPLICATION ASSURES THE GREATEST CAPTURE OF PATIENTS IN CLINICAL PRACTICE
Adamichou C; Nikolopoulos D; Genitsaridi I; Bortoluzzi A; Fanouriakis A; Papastefanakis E; Kalogiannaki E; Gergianaki I; Sidiropoulos P; Boumpas D; Bertsias G
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:381
THE HEMATOPOIETIC STEM CELLS (HSCS) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) REPROGRAM THEIR TRANSCRIPTOME: IMPLICATIONS FOR THE PATHOGENESIS OF THE DISEASE
Banos A; Grigoriou M; Filia A; Pavlidis P; Giannouli L; Karali V; Nikolopoulos D; Pieta A; Mitroulis I; Verginis P; Boumpas D
Visa fler

Utvalda forskningsbidrag

Reumatikerförbundet – Juniora Forskare
1 October 2025 - 1 October 2028

Forskningsbidrag

Ulla och Gustaf af Ugglas stiftelse 2025
1 October 2025 - 1 October 2026
Gustaf V:s 80-årsfond (2025-2027)
31 May 2025 - 31 May 2027
Alex och Eva Wallströms stiftelse
31 March 2025 - 31 March 2027
Gustaf V:s 80-årsfond (2024-2025)
31 May 2024 - 31 May 2025
Ulla och Gustaf af Ugglas stiftelse 2023
1 October 2023 - 1 October 2024
Ulla och Roland Gustafssons Donationsfond 2024
Ulla och Roland Gustafssons Donationsfond 2025
Swedish Rheumatism Association 2025
Reumatikerförbundet - Stiftelsen Sigrid Anderssons fond 2024
Åke Wibergs Stiftelse
X-Hide ”starting grant”

Anställningar

Forskningsspecialist, Medicin, Solna, Karolinska Institutet, 2025-
Postdoktor, Medicin, Solna, Karolinska Institutet, 2023-2025

Examina och utbildning

PhD, Immunology, Neuropsychiatric Lupus: Clinical and pathogenetic aspects, National and Kapodistrian University of Athens, 2022
MD, Medicine, National and Kapodistrian University of Athens, 2018

Artiklar

Alla övriga publikationer

Utvalda forskningsbidrag

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI